SOUL study showed Rybelsus® (semaglutide) tablets 14 mg reduced the risk of major adverse cardiovascular events (MACE) by 14% (ARR 2% absolute risk reduction at 3 years) vs placebo in adults with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney...
Hence then, the article about oral semaglutide 14 mg demonstrated superior reduction in risk of cardiovascular events in late breaking soul trial presented at the american college of cardiology was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Oral semaglutide 14 mg demonstrated superior reduction in risk of cardiovascular events in late-breaking SOUL trial presented at the American College of Cardiology )
Also on site :
- Psychologists Say This Common 3-Word Phrase Can Accidentally Shut Down a Conversation (Hint: It’s Not ‘That Doesn’t Work’)
- Martha Stewart’s Flannel Christmas Sheets Are 58% Off and Feature ‘Adorable’ Wreath, Dog, and Ski Village Designs
- Women astronauts outnumber men in NASA’s new class—they’re now halfway through training and set to earn around $150K with no overtime or hazard pay